Ribolytix is a Duke University spinout providing specialized CRO services for RNA-/RBP-targeting drug discovery. Drug developers in this space rely on indirect readouts, single reporter assays, or poorly translatable out-of-cell assays. These approaches are too narrow, artifact-prone, or not scalable. As a result, compounds frequently advance into costly animal studies with weak potency or hidden off-target liabilities that only become apparent in vivo. Ribolytix addresses this gap by enabling quantitative, in-cell measurement of drug-induced changes in endogenous RNA–protein interactions across the RBPome, delivering engagement IC₅₀ values and selectivity profiles to support hit-to-lead decision-making and early lead optimization.
| Website | http://www.ribolytix.com |
| Employees | 3 (1 on RocketReach) |
| Founded | 2025 |
| Address | 701 W Main Street Suite 200, Durham, North Carolina 27701, US |
| Industry | Biotechnology Research |
Looking for a particular Ribolytix employee's phone or email?
Johncarlo Kristofich is the Founder and CEO of Ribolytix.
1 people are employed at Ribolytix.
Ribolytix is based in Durham, North Carolina.